Living With Stage 4 Lung Cancer: Survival Rates, Treatments ...
Small Cell Vs. Non-small Cell Lung Cancer
Small cell and non-small cell are the two main types of lung cancer. There are several key differences, including the outlook for each.
In a person with small cell lung cancer, the cancerous cells appear small and round under a microscope. The cells of non-small cell lung cancer are larger.
Smoking is a major risk factor for both types. Of those who receive a diagnosis of small cell lung cancer, 95% have a history of smoking.
There are several subtypes of both small and non-small cell lung cancer. Non-small cell lung cancers include adenocarcinoma, squamous cell, and large cell carcinoma.
Small cell lung cancers vary depending on the expression of specific genes.
Some types are more aggressive than others, but generally, small cell lung cancer is more aggressive than non-small cell lung cancer.
Lung cancer — including both small and non-small cell types — is the third most common form of cancer among adults in the United States. Lung cancers account for 13% of new cancer diagnoses.
Small and non-small cell lung cancers cause similar symptoms. Sometimes, symptoms do not appear until the cancer reaches a later stage.
Symptoms include:
The symptoms of small and non-small cell lung cancers are similar, but small cell lung cancer spreads more rapidly.
A person may be more likely to experience symptoms after lung cancer has reached a later stage.
Does lung cancer affect women differently? Learn more here.
Can shoulder pain be a sign of lung cancer? Find out more.
Causes and risk factors for small and non-small cell lung cancer tend to be similar.
Smoking is the main risk factor. Cigarette smoke and the chemicals it contains can damage the lungs. This can lead to cellular changes that may result in cancer.
Additional risk factors include:
Smoking is a major risk factor for lung cancer. Find some ideas about how to quit here.
If a person sees a doctor about a persistent cough and other possible symptoms of lung cancer, the doctor will ask questions and take a medical history. They will also perform a physical examination.
If lung cancer may be present, the doctor will also request imaging scans, such as an X-ray or CT scan, and look for signs of a tumor, scarring, or a buildup of fluid.
They may also request samples of phlegm in order to perform a sputum test. This can help indicate whether cancer is present. The doctor will probably ask the person to provide a sample every morning for 3 days in a row.
Doctors may also perform a biopsy. This involves using a needle to take a sample of cells from the lungs for examination under a microscope. They may do this during surgery.
A biopsy can show:
Sometimes, the doctor requests a bronchoscopy. This procedure involves inserting a tool with a built-in camera through the mouth or nose and into the lungs. This helps them see the area and take tissue samples.
They may also carry out other tests to determine whether the cancer has spread beyond the lungs.
What does lung cancer look like? Find out here.
StagingThe stage of cancer describes how far it has spread within the body.
There are different ways to describe the stages. One simple way is:
However, each type of lung cancer has its own specific method of staging.
Non-small cell lung cancerFor this type of cancer, doctors typically use a 5-stage system.
Doctors generally categorize small cell lung cancer with one of two stages:
Some doctors use further staging for small cell lung cancer.
Can a person have both types?Around 5–28% of small cell lung cancer cases are "mixed." This means that the person has small and non-small cell lung cancers. Research suggests that it may be easier to treat mixed cancer than small cell lung cancer alone.
After making a diagnosis, a doctor will describe the treatment options and develop a treatment plan.
Factors that affect the plan will include:
As each person's situation is different, treatment will vary accordingly.
Non-small cell lung cancerTreatment options for non-small cell lung cancer include:
For small cell lung cancer, treatment mainly aims to manage the disease.
Options include:
Doctors may use a combination of treatments for lung cancer, depending upon an individual's needs, the stage of the cancer, and the location of the tumor.
Experts use past statistics to estimate the percentage of people who are likely to live for 5 or more years after a diagnosis of cancer. These estimations are called survival rates.
They represent averages and do not take into account factors such as a person's age or overall health.
Non-small cell lung cancerFor non-small cell lung cancer, the American Cancer Society (ACS) reports the following relative 5-year survival rates:
The overall average likelihood of living for at least another 5 years is 26%.
Small cell lung cancerThe ACS estimates the following 5-year survival rates for people with small cell lung cancer:
The overall average likelihood of living for at least another 5 years after a diagnosis of small cell lung cancer is 7%.
Other factors that may affect survival rates include whether the cancer has come back after treatment and a person's age. Recurring cancer and advanced age can have a negative effect on survival rates.
There are two main types of lung cancer: small cell and non-small cell. Small cell lung cancer is less common and more aggressive.
Quitting smoking — or never smoking — can significantly reduce the risk of developing any type of lung cancer.
Read this article in Spanish.
Significant Progress In Small-cell Lung Cancer Research
Small-cell lung cancer is a particularly aggressive type of tumor with a consistently high mortality rate. In recent years, the research of scientists at MedUni Vienna's Department of Thoracic Surgery has significantly contributed to a better understanding and new therapeutic approaches in this malignant disease. Their comprehensive overview of new insights and advances in small-cell lung cancer has just been published in CA: A Cancer Journal for Clinicians, the highest-ranked international scientific journal.
The key findings of Balazs Döme's team from the Department of Thoracic Surgery at MedUni Vienna primarily consist of new insights into the biology and heterogeneity of small-cell lung cancer (SCLC). In collaboration with colleagues from Sweden, the Czech Republic, Hungary, and the United States, the researchers previously demonstrated that SCLC can be categorized into different subgroups which are associated with varying clinical behaviors and potentially new therapeutic strategies. They also demonstrated that certain combinations of multiple drugs represent a particularly promising therapeutic approach in patients with characteristic molecular SCLC profiles.
Based on these profound research contributions, the team from the Translational Thoracic Oncology Research Laboratory at MedUni Vienna's Department of Thoracic Surgery was recently invited to present a comprehensive overview of recent advances in small-cell lung cancer. The review from Balazs Döme and his team has now been published in the journal CA: A Cancer Journal for Clinicians, the flagship journal of the American Cancer Society with the highest impact factor (286) of any scientific journal worldwide.
"We are delighted that our research achievements have received such high recognition," says Konrad Hötzenecker from the Department of Thoracic Surgery. "This provides an optimal base to further expand the clinical and translational lung cancer research activities of the Department of Thoracic Surgery at the Medical University of Vienna as one of the leading centers," emphasizes the newly appointed Professor of Thoracic Surgery and Director of the Department Clemens Aigner.
Expediting the development of personalized therapies
Approximately 15 percent of lung cancer patients are affected by small-cell lung cancer. This particularly aggressive tumor, which usually occurs in smokers, grows rapidly, has an increased tendency to metastasize, and a high mortality rate. According to Balazs Döme, conventional therapies have reached their plateau of effectiveness in SCLC. "With our research work, we have already created the basis for the development of targeted, personalized therapeutic approaches, which we now want to advance further," Döme states, announcing further research.
Big Changes In Small Cell Lung Cancer Give Patients Options They Never Had Before
(Diane Mulligan)
- Lung cancer is the deadliest of all major cancers, with Small Cell Lung Cancer (SCLC) patients having a significantly lower survival rate than non-small cell lung cancer patients (NSCLC).
In 2012, the National Cancer Institute identified SCLC as a top priority. More targeted and personalized treatments are expected to be released soon. There are also many clinical trials focusing on SCLC. The new research is leading to new treatments and new hope, which can't come quickly enough for SCLC patients.
SCLC is different from NSCLC, which is the most common form of lung cancer. It is the most aggressive form of lung cancer and the one most closely associated with smokers. The SCLC tumors morph as they try to survive. They change their form, trying to hide from the current treatment.
People are also reading…
Lung cancer researchers are now focused on treatments that target specific tumors.
Dr. Triparna Sen, Associate Professor at Icahn School of Medicine at Mt. Sinai Health System says, "Do we have targets? Yes, we do have targets. Do they look promising? Yes, they do look promising. It will not be one size fits all."
Most SCLC patients are treated with chemotherapy, but there have been recent advances in using immunotherapy along with chemotherapy. Patients who have finished their initial treatment now have new options and should talk to their doctor about new treatments being researched in clinical trials. In most of these trials, one set of patients receives the latest approved treatment while the other set receives the treatment being researched.
According to Lung Cancer Foundation of America Founder Kim Norris, "These clinical trials are where patients are getting the gold standard of care. They may be receiving the treatments of tomorrow, today."
It was only last year when the first SCLC treatment breakthrough was announced. Then researchers identified a subset of SCLC patients who appear to respond to drugs that are already proven cancer fighters; the proteins in the tumors of these patients make them more receptive to targeted therapies.
The Lung Cancer Foundation of America provides initial funding to young investigators who are studying all types of lung cancer. The group was organized after the co-founder, Kim Norris, realized that although it was the deadliest of all the major cancers, lung cancer received the least amount of federal funding in relation to other major cancers.
Norris says, "It's that funding that allows the best and brightest young investigators to choose to study lung cancer."
To find out the latest on lung cancer research and how you can help, you can go to lcfamerica.Org.
Above image: Dr. Triparna Sen, Associate Professor at Icahn School of Medicine at Mt. Sinai Health System
Get local news delivered to your inbox!
Comments
Post a Comment